Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
09 2023
Historique:
received: 17 06 2022
accepted: 05 07 2023
medline: 11 9 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: ppublish

Résumé

Linkage and candidate gene studies have identified several breast cancer susceptibility genes, but the overall contribution of coding variation to breast cancer is unclear. To evaluate the role of rare coding variants more comprehensively, we performed a meta-analysis across three large whole-exome sequencing datasets, containing 26,368 female cases and 217,673 female controls. Burden tests were performed for protein-truncating and rare missense variants in 15,616 and 18,601 genes, respectively. Associations between protein-truncating variants and breast cancer were identified for the following six genes at exome-wide significance (P < 2.5 × 10

Identifiants

pubmed: 37592023
doi: 10.1038/s41588-023-01466-z
pii: 10.1038/s41588-023-01466-z
pmc: PMC10484782
doi:

Types de publication

Meta-Analysis Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1435-1439

Subventions

Organisme : Wellcome Trust
ID : 203477/Z/16/Z
Pays : United Kingdom

Investigateurs

Benita Kiat-Tee Tan (BK)
Veronique Kiak Mien Tan (VKM)
Su-Ming Tan (SM)
Geok Hoon Lim (GH)
Ern Yu Tan (EY)
Peh Joo Ho (PJ)
Alexis Jiaying Khng (AJ)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Dorling, L. et al. Breast cancer risk genes—association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 (2021).
pubmed: 33471991 doi: 10.1056/NEJMoa1913948
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
pubmed: 29059683 pmcid: 5798588 doi: 10.1038/nature24284
Lee, S., Gonçalo, Boehnke, M. & Lin, X. Rare-variant association analysis: study designs and statistical tests. Am. J. Hum. Genet. 95, 5–23 (2014).
pubmed: 24995866 pmcid: 4085641 doi: 10.1016/j.ajhg.2014.06.009
Hujoel, M. L. A., Gazal, S., Loh, P.-R., Patterson, N. & Price, A. L. Liability threshold modeling of case–control status and family history of disease increases association power. Nat. Genet. 52, 541–547 (2020).
pubmed: 32313248 pmcid: 7210076 doi: 10.1038/s41588-020-0613-6
Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 (2021).
pubmed: 33471974 pmcid: 8127622 doi: 10.1056/NEJMoa2005936
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 47, D886–D894 (2019).
pubmed: 30371827 doi: 10.1093/nar/gky1016
Vroling, B. & Heijl, S. White paper: the helix pathogenicity prediction platform. Preprint at arXiv https://doi.org/10.48550/arXiv.2104.01033 (2021).
Xia, Y., Wu, Z., Su, B., Murray, B. & Karin, M. JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev. 12, 3369–3381 (1998).
pubmed: 9808624 pmcid: 317229 doi: 10.1101/gad.12.21.3369
Wagner, E. F. & Nebreda, Á. R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537–549 (2009).
pubmed: 19629069 doi: 10.1038/nrc2694
Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
doi: 10.1038/nature11412
Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54 (2016).
pubmed: 27135926 pmcid: 4910866 doi: 10.1038/nature17676
Easton, D. F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
pubmed: 17529967 pmcid: 2714974 doi: 10.1038/nature05887
Fachal, L. et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat. Genet. 52, 56–73 (2020).
pubmed: 31911677 pmcid: 6974400 doi: 10.1038/s41588-019-0537-1
Dylan et al. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am. J. Hum. Genet. 96, 5–20 (2015).
doi: 10.1016/j.ajhg.2014.11.009
Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542–1548 (2003).
pubmed: 12791985 doi: 10.1126/science.1083430
Zhang, H. et al. ATRIP deacetylation by SIRT2 drives ATR checkpoint activation by promoting binding to RPA-ssDNA. Cell Rep. 14, 1435–1447 (2016).
pubmed: 26854234 pmcid: 4758896 doi: 10.1016/j.celrep.2016.01.018
Nacak, T. G., Leptien, K., Fellner, D., Augustin, H. G. & Kroll, J. The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis. J. Biol. Chem. 281, 5065–5071 (2006).
pubmed: 16356934 doi: 10.1074/jbc.M509073200
Smith, M. J. et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology 84, 141–147 (2015).
pubmed: 25480913 pmcid: 4336087 doi: 10.1212/WNL.0000000000001129
Paganini, I. et al. Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur. J. Hum. Genet. 23, 963–968 (2015).
pubmed: 25335493 doi: 10.1038/ejhg.2014.220
Ferru, A. et al. The status of CDKN2A α (p16INK4A) and β (p14ARF) transcripts in thyroid tumour progression. Br. J. Cancer 95, 1670–1677 (2006).
pubmed: 17117177 pmcid: 2360765 doi: 10.1038/sj.bjc.6603479
Rossi, M. et al. Familial melanoma: diagnostic and management implications. Dermatol. Pract. Concept. 9, 10–16 (2019).
pubmed: 30775140 pmcid: 6368081 doi: 10.5826/dpc.0901a03
Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M. & Dong, Z. Implications of genetic and epigenetic alterations of CDKN2A (p16 INK4a) in cancer. EBioMedicine 8, 30–39 (2016).
pubmed: 27428416 pmcid: 4919535 doi: 10.1016/j.ebiom.2016.04.017
Laduca, H. et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet. Med. 22, 407–415 (2020).
pubmed: 31406321 doi: 10.1038/s41436-019-0633-8
Borg, A. K. et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl Cancer Inst. 92, 1260–1266 (2000).
pubmed: 10922411 doi: 10.1093/jnci/92.15.1260
Coquel, F. et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature 557, 57–61 (2018).
pubmed: 29670289 doi: 10.1038/s41586-018-0050-1
Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480, 379–382 (2011).
pubmed: 22056990 doi: 10.1038/nature10623
Stankovic, S. et al. Genetic susceptibility to earlier ovarian ageing increases de novo mutation rate in offspring. Preprint at medRxiv https://doi.org/10.1101/2022.06.23.22276698 (2022).
Li, Q. & Lozano, G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19, 34–41 (2013).
pubmed: 23262034 doi: 10.1158/1078-0432.CCR-12-0053
Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat. Genet. 45, 392–398 (2013).
pubmed: 23535733 pmcid: 3771695 doi: 10.1038/ng.2561
Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
pubmed: 24429628 pmcid: 4975511 doi: 10.1038/nature12981
Sondka, Z. et al. The COSMIC cancer gene census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
pubmed: 30293088 pmcid: 6450507 doi: 10.1038/s41568-018-0060-1
Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S. & Hirschhorn, J. N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33, 177–182 (2003).
pubmed: 12524541 doi: 10.1038/ng1071
Lee, A. et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet. Med. 21, 1708–1718 (2019).
pubmed: 30643217 pmcid: 6687499 doi: 10.1038/s41436-018-0406-9
Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
pubmed: 25826379 pmcid: 4380465 doi: 10.1371/journal.pmed.1001779
Collins, R. What makes UK Biobank special? Lancet 379, 1173–1174 (2012).
pubmed: 22463865 doi: 10.1016/S0140-6736(12)60404-8
Backman, J. D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628–634 (2021).
pubmed: 34662886 pmcid: 8596853 doi: 10.1038/s41586-021-04103-z
Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942–948 (2021).
pubmed: 34183854 doi: 10.1038/s41588-021-00885-0
Chong Jin, O. & Gilbert, E. G. The Gilbert-Johnson-Keerthi distance algorithm: a fast version for incremental motions. Proceedings of International Conference on Robotics and Automation Vol. 2, pp. 1183–1189 (IEEE, 1997).
Halldorsson, B. V. et al. The sequences of 150,119 genomes in the UK Biobank. Nature 607, 732–740 (2022).
pubmed: 35859178 pmcid: 9329122 doi: 10.1038/s41586-022-04965-x
Eggertsson, H. P. et al. GraphTyper2 enables population-scale genotyping of structural variation using pangenome graphs. Nat. Commun. 10, 5402 (2019).
pubmed: 31776332 pmcid: 6881350 doi: 10.1038/s41467-019-13341-9
McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4
Yates, A. D. et al. Ensembl 2020. Nucleic Acids Res. 48, D682–D688 (2019).
pmcid: 7145704
O’Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 44, D733–D745 (2016).
pubmed: 26553804 doi: 10.1093/nar/gkv1189
Liu, J. Z., Erlich, Y. & Pickrell, J. K. Case–control association mapping by proxy using family history of disease. Nat. Genet. 49, 325–331 (2017).
pubmed: 28092683 doi: 10.1038/ng.3766
Schmidt, M. K. et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J. Clin. Oncol. 34, 2750–2760 (2016).
pubmed: 27269948 pmcid: 5019754 doi: 10.1200/JCO.2016.66.5844
Greenland, S. & Longnecker, M. P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am. J. Epidemiol. 135, 1301–1309 (1992).
pubmed: 1626547 doi: 10.1093/oxfordjournals.aje.a116237
Longnecker, M. P., Berlin, J. A., Orza, M. J. & Chalmers, T. C. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA 260, 652–656 (1988).
pubmed: 3392790 doi: 10.1001/jama.1988.03410050072032
Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet. 88, 586–598 (2011).
pubmed: 21565292 pmcid: 3146723 doi: 10.1016/j.ajhg.2011.04.014
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Ogata, H. et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29–34 (1999).
pubmed: 9847135 pmcid: 148090 doi: 10.1093/nar/27.1.29
Gillespie, M. et al. The Reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687–D692 (2022).
pubmed: 34788843 doi: 10.1093/nar/gkab1028
Rouillard, A. D. et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford) 2016, baw100 (2016).
pubmed: 27374120 doi: 10.1093/database/baw100
Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb.) 2, 100141 (2021).
pubmed: 34557778
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393 pmcid: 3106198 doi: 10.1093/bioinformatics/btr260
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004

Auteurs

Naomi Wilcox (N)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Martine Dumont (M)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Anna González-Neira (A)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Sara Carvalho (S)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Charles Joly Beauparlant (C)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Marco Crotti (M)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Craig Luccarini (C)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Penny Soucy (P)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Stéphane Dubois (S)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Rocio Nuñez-Torres (R)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Guillermo Pita (G)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Eugene J Gardner (EJ)

MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Joe Dennis (J)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

M Rosario Alonso (MR)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Nuria Álvarez (N)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Caroline Baynes (C)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Annie Claude Collin-Deschesnes (AC)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Sylvie Desjardins (S)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Heiko Becher (H)

Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sabine Behrens (S)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Manjeet K Bolla (MK)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Jose E Castelao (JE)

Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sten Cornelissen (S)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Thilo Dörk (T)

Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.

Christoph Engel (C)

Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.

Manuela Gago-Dominguez (M)

Cancer Genetics and Epidemiology Group, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) Foundation, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.

Pascal Guénel (P)

Team 'Exposome and Heredity,' CESP, Gustave Roussy, INSERM, University Paris-Saclay, UVSQ, Villejuif, France.

Andreas Hadjisavvas (A)

Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.

Eric Hahnen (E)

Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Mikael Hartman (M)

Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore City, Singapore.
Department of Surgery, National University Health System, Singapore City, Singapore.
Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore.

Belén Herráez (B)

Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Audrey Jung (A)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Renske Keeman (R)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marion Kiechle (M)

Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.

Jingmei Li (J)

Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore City, Singapore. lijm1@gis.a-star.edu.sg.

Maria A Loizidou (MA)

Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.

Michael Lush (M)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Kyriaki Michailidou (K)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Biostatistics Unit, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.

Mihalis I Panayiotidis (MI)

Department of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.

Xueling Sim (X)

Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore City, Singapore.

Soo Hwang Teo (SH)

Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Malaysia.
Department of Surgery, Faculty of Medicine, University of Malaya, UM Cancer Research Institute, Kuala Lumpur, Malaysia.

Jonathan P Tyrer (JP)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Lizet E van der Kolk (LE)

Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands.

Cecilia Wahlström (C)

Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Qin Wang (Q)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

John R B Perry (JRB)

MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Javier Benitez (J)

Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Marjanka K Schmidt (MK)

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands.

Rita K Schmutzler (RK)

Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Paul D P Pharoah (PDP)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Arnaud Droit (A)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.
Département de Médecine Moléculaire, Faculté de Médecine, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, Quebec, Canada.

Alison M Dunning (AM)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.

Anders Kvist (A)

Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Peter Devilee (P)

Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.

Douglas F Easton (DF)

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. dfe20@medschl.cam.ac.uk.
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. dfe20@medschl.cam.ac.uk.

Jacques Simard (J)

Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH